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ABSTRACT 26 
FOXP3+ regulatory T (Treg) cells are essential for maintaining immunological tolerance. 27 
Given their importance in immune-related diseases, cancer and obesity, there is increasing 28 
interest in targeting the Treg cell compartment therapeutically. New pharmacological inhibitors 29 
that specifically target the pro-survival protein MCL-1 may provide this opportunity, as Treg 30 
cells are particularly reliant upon this protein. However, there are two distinct isoforms of 31 
MCL-1; one located at the outer mitochondrial membrane (OMM) that is required to 32 
antagonize apoptosis, and another at the inner mitochondrial membrane (IMM) that is reported 33 
to maintain IMM structure and metabolism via ATP production during oxidative 34 
phosphorylation. We set out to elucidate the relative importance of these distinct biological 35 
functions of MCL-1 in Treg cells to assess whether MCL-1 inhibition might impact upon the 36 
metabolism of cells able to resist apoptosis. Conditional deletion of Mcl1 in FOXP3+ Treg cells 37 
resulted in a lethal multi-organ autoimmunity due to the depletion of the Treg cell 38 
compartment. This striking phenotype was completely rescued by concomitant deletion of the 39 
apoptotic effector proteins BAK and BAX, indicating that apoptosis plays a pivotal role in the 40 
homeostasis of Treg cells. By contrast, MCL-1-deficient Treg cells rescued from apoptosis 41 
displayed normal metabolic capacity. Moreover, pharmacological inhibition of MCL-1 in Treg 42 
cells resistant to apoptosis did not perturb their mitochondrial membrane potential or metabolic 43 
function. We conclude that Treg cells require MCL-1 only to antagonize apoptosis and not for 44 
metabolism. Therefore, MCL-1 inhibition could be used to manipulate Treg cell survival for 45 
clinical benefit without effecting the metabolic fitness of cells resisting apoptosis.  46 
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INTRODUCTION 47 
Apoptosis is an evolutionally conserved cell death mechanism essential for development, 48 
homeostasis and tumour suppression. Apoptosis can be triggered through the B cell 49 
lymphoma 2 (BCL-2)-regulated (or intrinsic or mitochondrial) pathway 1. The pathway is 50 
regulated by members of the BCL-2 family of proteins in activities that converge on the 51 
mitochondrial outer membrane. During apoptosis, the effector proteins, BAK and/or BAX 52 
become activated, changing conformation to permeabilize the outer mitochondrial 53 
membrane (OMM) 2. Mitochondrial proteins, such as cytochrome c and SMAC/DIABLO, 54 
then leak out of the mitochondria and initiate a caspase activation cascade to mediate cell 55 
demolition 3. Therefore, the activation of BAX and/or BAK represents the fulcrum of the 56 
BCL-2-regulated pathway of apoptosis. In healthy cells, pro-survival proteins such as BCL-57 
2, BCL-XL and MCL-1 restrain BAX and BAK to prevent apoptosis. Cellular stresses, such 58 
as g-irradiation, growth factor deprivation or hypoxia induce activation or upregulation of 59 
the pro-apoptotic BH3-only members of the BCL-2 family, such as BIM, PUMA or NOXA 60 
4. The BH3-only proteins can interact with the pro-survival BCL-2 family members to relieve 61 
their inhibition of BAX and BAK, and can also directly activate these effector proteins to 62 
induce apoptosis 5. Different cell types have different expression profiles of the various BCL-63 
2 family proteins and the cellular response to different cytotoxic stimuli can therefore vary. 64 
For example, platelets are particularly reliant upon BCL-XL for their survival, whereas many 65 
lymphocyte subsets are dependent upon MCL-1, and to a lesser extent, upon BCL-2 or BCL-66 
XL 6. 67 
 68 
Regulatory T (Treg) cells are a subset of CD4+ T cells essential for maintaining 69 
immunological tolerance by constraining the activation, proliferation and cytokine 70 
production of CD4+ and CD8+ T cells 7. Treg cells are characterised by expression of the 71 
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transcription factor forkhead box P3 (FOXP3) 8, which drives the unique transcriptional 72 
signature of this cell population, and also by high levels of IL-2 receptor (IL-2R or CD25) 73 
on the cell surface 9. These high levels of IL-2R play a key role in the unique homeostatic 74 
properties of Treg cells 10, and also contribute to their suppressive function through 75 
outcompeting conventional T cells for available IL-2. The importance of Treg cells in 76 
maintaining immune homeostasis is underscored by the fatal autoimmune phenotype that 77 
results from the disruption of FoxP3 in mice and humans 8, 11, 12, 13, 14, 15. Of note, Treg cells 78 
have also been implicated in a wide variety of other diseases 16 and there is increasing interest 79 
in targeting the Treg cell compartment therapeutically to augment immune responses in 80 
diseases, such as chronic infections, cancer and obesity induced metabolic disease 17 18, 19, 20, 81 
21. 82 
 83 
Treg cell survival and homeostasis relies upon the pro-survival protein MCL-1 22. Although 84 
many other immune cell types require a basal level of MCL-1 expression for their survival 85 
23, Treg cells express relatively higher amounts of MCL-1 than other T cell subsets 22, in part 86 
controlled by IL-2R signalling 10, 22. The first MCL-1 inhibitor, S63845, showed promising 87 
results in many pre-clinical models of human cancers 24, 25, 26 and was assessed to be safe and 88 
tolerable in a mouse model of humanised Mcl-1 27. Recently, clinical trials have commenced 89 
for several MCL-1 inhibitors, including S64315/MIK665 (a derivative of S6384524), AMG 90 
176 and AMG 397 (NCT0299248, NCT02675452 and NCT03465540, respectively) in 91 
cancer 28. An important consideration in the deployment of MCL-1 inhibitors in the clinic is 92 
their potential to inhibit the two distinct isoforms and functions of MCL-1. One isoform is 93 
located at the outer mitochondrial membrane (OMM) and restrains BAX plus BAK and is 94 
thus required to inhibit apoptosis. The other MCL-1 isoform is located at the inner 95 
mitochondrial membrane (IMM) and is essential for IMM structure and plays a role in 96 
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metabolism by impacting ATP production during oxidative phosphorylation 29, 30. Treg cells 97 
from mice express both of these isoforms 22. Although inhibiting the pro-survival form of 98 
MCL-1 at the OMM is desirable for killing cancer cells, there is evidence that the MCL-1 99 
inhibitors, MIM-1 and S63845 can also disrupt the IMM form of MCL-1 in human stem 100 
cells 31. Hence, as MCL-1 inhibitors progress in clinical development, it will be imperative 101 
to dissect the relative importance of the two major functions of MCL-1 in key cell types, 102 
such as lymphocytes, to understand the potential impacts of MCL-1 inhibition and 103 
indications beyond directly targeting cancer cells. 104 
 105 
Here, we study MCL-1 function in Treg cells because they are highly reliant upon MCL-1 and 106 
impaired survival or metabolic function in Treg cells induces clear, fatal immune outcomes in 107 
vivo 22, 33. MCL-1-deficiency in Treg cells resulted in fatal multi-organ immune pathology, 108 
resembling that observed in the Foxp3-deficient scurfy mutant mouse. This phenotype could 109 
be completely rescued by the genetic deletion of pro-apoptotic Bak and Bax, indicating that 110 
only the pro-survival function of MCL-1 is essential for Treg cell homeostasis and immune 111 
tolerance. MCL-1-deficient Treg cells rescued from apoptosis also had normal metabolic 112 
capacity. Furthermore, we demonstrate that the inhibition of MCL-1 with S63845 did not 113 
perturb the metabolic function of Treg cells rendered refractory to apoptosis. These data 114 
suggest that MCL-1 inhibition could be used to manipulate Treg cell survival for clinical 115 
benefit, without impacting the metabolic fitness of the remaining Treg cells or potentially other 116 
lymphocytes. 117 
 118 
RESULTS 119 
Loss of MCL-1 in Treg cells drives a fatal multi-organ autoimmunity that is rescued by 120 
BAK deficiency  121 
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To determine the impact of MCL-1 loss on Treg cell homeostasis, we inter-crossed mice with 122 
floxed Mcl1 alleles (Mcl1fl/fl mice) 34 with another strain expressing the Cre-recombinase and 123 
a YFP reporter under the control of the Treg-specific gene, Foxp3, (FoxP3Cre-IRES-YFP mice) 35. 124 
This inter-cross generated mice with Treg cell-specific deletion of Mcl1 (hereafter referred to 125 
as Mcl1DFoxP3 mice). We confirmed MCL-1-deficiency was specific to FOXP3+ cells by 126 
assaying the amount of MCL-1 protein by intracellular flow cytometry in CD4+ FOXP3- T and 127 
CD4+ FOXP3+ Treg cells (Figure 1A). Accordingly, we observed a significantly lower 128 
fluorescence intensity of MCL-1 specifically in the Treg cell population compared to CD4+ 129 
FOXP3- T cells (Figure 1B) or Treg cells from MCL-1-sufficient mice (not shown). Consistent 130 
with previous findings 22, MCL-1-deficiency in Treg cells led to the development of a lethal 131 
lympho-infiltrative disease, with a median survival age of 76 days (Figure 1C). The auto-132 
inflammatory phenotype observed in Mcl1DFoxP3 mice resembled that observed in scurfy mice 133 
36, 37, albeit with a slightly slower kinetics (Figure 1C). There was significant elevation of IgE 134 
in the sera of Mcl1DFoxP3 compared to wild-type (WT) mice (Figure 1D) and histological 135 
analysis revealed severe lymphocytic infiltration of a range of peripheral organs, including the 136 
lung, pancreas and salivary glands (Figure 1E and F); all hallmarks of the multi-organ 137 
autoimmunity accompanying Treg cell deficiency consistent with the early lethality in 138 
Mcl1DFoxP3 mice. 139 
 140 
To test whether abrogation of the BCL-2-regulated pathway of apoptosis was sufficient to 141 
prevent disease in Mcl1DFoxP3 mice, they were inter-crossed with Baxfl/fl Bak-/- 38 mice to create 142 
Mcl1DFoxP3 BaxDFoxP3 Bak-/- animals. These mice survived to 125 days without any overt signs 143 
of pathology (Figure 1C). In addition, serum IgE and all histological parameters in these 144 
Mcl1DFoxP3 BaxDFoxP3 Bak-/- mice were comparable to wild-type counterparts (Figure 1D-F). 145 
Three additional Mcl1DFoxP3 BaxDFoxP3 Bak-/- mice were aged to 228 days and also survived free 146 
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of disease. Interestingly, the loss of BAK alone was sufficient to rescue lethal auto-147 
inflammation in Mcl1DFoxP3 mice (Figure 1C), consistent with the predilection for MCL-1 to 148 
interact with this apoptotic effector compared to BAX 39, 40. These results indicate that 149 
impairing BAK- (and to a lesser extent also BAX-) mediated apoptosis rescues the lethal 150 
autoimmunity observed in Mcl1DFoxP3 mice. 151 
 152 
Deletion of BAK and BAX in Mcl1DFoxP3 mice is sufficient to restore Treg cells and 153 
immune tolerance 154 
BAK and BAX are essential for execution of the intrinsic pathway of apoptosis but are 155 
dispensable for the metabolic function of MCL-1. Therefore, we next assessed how 156 
concomitant loss of BAK and BAX prevented disease in Mcl1DFoxP3 mice and whether Treg 157 
cells rescued by prevention of apoptosis exhibited signs of perturbed differentiation or 158 
phenotype suggestive of impaired metabolism. Consistent with the kinetics of Foxp3Cre-159 
mediated deletion, Mcl1DFoxP3 mice generated normal numbers of CD4+FOXP3+ Treg cells in 160 
the thymus (Figure 2A, B). As previously reported 22, BaxDFoxP3 Bak-/- mice have a significant 161 
proportional and numerical increase in the thymic Treg compartment compared to WT controls 162 
(Figure 2A, B). This increase was maintained with concomitant loss of Mcl1 in Treg cells 163 
(Figure 2A, B), indicating that thymic Treg cell maturation was normal or enhanced. 164 
 165 
Treg cells in the peripheral lymphoid organs (spleen and lymph nodes) were substantially 166 
diminished in Mcl1DFoxP3 mice compared to WT controls (Figure 2C, D), consistent with the 167 
notion that loss of this population led to loss of immune tolerance and fatal autoimmunity 22. 168 
BaxDFoxP3 Bak-/- mice had a greater proportion and number of Treg cells in the periphery 169 
compared to WT controls (Figure 2C, D). These BAX- and BAK-deficient Treg cells had 170 
comparable suppressive capacity to Treg cells from WT controls (Supplementary Figure S1A). 171 
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The Treg population in Mcl1DFoxP3 BaxDFoxP3 Bak-/- mice was expanded to the same extent as 172 
BaxDFoxP3 Bak-/- controls (Figure 2C, D), indicating that loss of the downstream apoptotic 173 
effector proteins completely rescued the death of MCL-1-deficient Treg cells. 174 
  175 
The activation of CD4+FOXP3- and CD8+ T cell populations inversely correlated with Treg 176 
cell numbers. Mcl1DFoxP3 mice had an approximately 2- to 3-fold increase in the proportion and 177 
number of activated CD44highCD62Llow cells compared to WT mice (Figure 3A, B), consistent 178 
with a severe defect in immune tolerance. By contrast, CD4+FOXP3- and CD8+ cell activation 179 
in Mcl1DFoxP3 BaxDFoxP3 Bak-/- mice was comparable to WT controls (Figure 3A, B). These data 180 
indicate that abrogation of BAK/BAX-mediated apoptosis is sufficient to restore Treg cell 181 
homeostasis and immune tolerance in the absence of the pro-survival protein, MCL-1, at least 182 
until 228 days. Furthermore, MCL-1-deficient Treg cells are capable of suppressing the 183 
activation of autoreactive CD4+ and CD8+ cells to preserve immune tolerance. 184 
 185 
Neither genetic deletion of Mcl1 nor pharmacological inhibition of MCL-1 affects Treg 186 
cell metabolism 187 
Deletion of Mcl1 has been reported to impair the metabolic function in other cell types, such 188 
as cardiomyocytes and stem cells 29, 30, 31. Our data indicated that Mcl1-deficient Treg cells 189 
rendered resistant to apoptosis had normal homeostasis and function. However, since Treg cells 190 
also express the lower molecular weight isoform of MCL-1 that localizes to the IMM 22 (as do 191 
those from BaxDFoxP3 Bak-/- mice, (Supplementary Figure S1B)), it was important to directly 192 
test their metabolic capacity. Quantification of mitochondrial membrane potential, using 193 
Mitotracker Orange staining, in Treg cells from WT, BaxDFoxP3 Bak-/- and Mcl1DFoxP3 BaxDFoxP3 194 
Bak-/- mice was performed (the paucity of Treg cells in Mcl1DFoxP3 mice precluded their 195 
analysis). Consistent with a previous report, wWe We observed somewhat reduced 196 
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mitochondrial membrane potential in Treg cells lacking BAX and BAK compared to WT cells 197 
(Figure 4A). However, compared to BaxDFoxP3 Bak-/- controls, MCL-1 deficient Treg cells did 198 
not show substantial changes in oxidative membrane potential, indicating that overall 199 
mitochondrial membrane potential was comparable (Figure 4A). 200 
 201 
For a more detailed analysis of Treg cell metabolic capacity, these cells were purified from 202 
BaxDFoxP3 Bak-/- and Mcl1DFoxP3 BaxDFoxP3 Bak-/- mice and analysed on the Seahorse XF platform 203 
to detect changes in respiration in MCL-1-deficient Treg cells. Since the numbers of Treg cells 204 
that can be recovered from mice was limiting, we performed three independent experiments 205 
each with technical replicates of 600,000 cells pooled from n=2-5 mice. Representative data 206 
from one experiment are shown in Figure 4B-D and the other replicates presented in 207 
Supplementary Figure S2. Despite the reduction in mitochondrial membrane potential detected 208 
with Mitotracker staining, Treg cells from BaxDFoxP3 Bak-/- mice did not demonstrate gross 209 
defects in respiration compared to those from WT mice across multiple experiments (Fig 4B, 210 
C; Supplementary Figure S2A, C). This finding is consistent with previous data showing that 211 
BAX- and BAK-deficient MEF have normal respiratory capacity 41 and our findings that Treg 212 
cells from BaxDFoxP3 Bak-/- mice retain normal functional capacity (Supplementary Figure 213 
S2A). 214 
 215 
As MCL-1 was reported to be required for the oligomerization of the F1F0-ATP Synthase 216 
complex in some cell types 29, we anticipated that Treg cells lacking MCL-1 would have 217 
impaired ATP production through mitochondrial oxidative phosphorylation. The oxygen 218 
consumption rate (OCR) is a surrogate of mitochondrial respiration. Basal respiration is 219 
calculated as the difference between non-mitochondrial oxygen consumption (i.e. the OCR 220 
following inhibition of the RC complex I and complex III with the compounds Rotenone and 221 
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Antimycin A, respectively) and the initial OCR before the addition of Oligomycin (Figure 4B, 222 
C; Supplementary Figure S2A, C). We found that Treg cells from Mcl1DFoxP3 BaxDFoxP3 Bak-223 
/- mice had similar basal respiration as BaxDFoxP3 Bak-/- controls (Figure 4B, C; Supplementary 224 
Figure S2A, C). Loss of IMM MCL-1 has also been reported to reduce maximal respiration 225 
29, which is calculated as the difference between the OCR following addition of the uncoupler 226 
FCCP, and non-mitochondrial oxygen consumption (Figure 4B, D; Supplementary Figure 227 
S2B, D). We observed no significant differences in maximal respiration between Treg cells 228 
from the Mcl1DFoxP3 BaxDFoxP3 Bak-/- and the control (Figure 4B, D; Supplementary Figure 229 
S2B, D). These data indicate that the genetic deletion of Mcl1 does not affect the metabolic 230 
function of Treg cells when they are protected from apoptosis by the loss of BAX and BAK. 231 
 232 
Clinical trials of the MCL-1 inhibitor, S64315/MIK665 (a derivative of S63845) have 233 
commenced. Although it has not been directly demonstrated that S63845 interacts with the 234 
IMM isoform of MCL-1, it has been published that it can disrupt interactions between MCL-1 235 
and the matrix-localized protein, OPA-1 9. Therefore, we next tested whether S63845 had any 236 
direct or indirect effects on metabolism in Treg cells incapable of undergoing apoptosis due to 237 
the loss of BAX and BAK. Treg cells were harvested from haematopoietic chimeras 238 
reconstituted with bone marrow from Bak-/- mice (to obtain a sufficient number of cells) and 239 
treated with doses of S63845 that were either sub-optimal (0.1 µM) or sufficient (1 µM) for 240 
induction of apoptosis in WT Treg cells (Supplementary Figure S3) or a vehicle control and 241 
analysed on the Seahorse XF platform (Figure 4E). Treatment with S63845 had no significant 242 
impact on either basal (Figure 4F) or maximal (Figure 4G) oxygen consumption. Therefore, 243 
the data from the genetic and pharmacological inhibition collectively indicate that MCL-1 is 244 
dispensable for Treg cell metabolism. 245 
 246 
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DISCUSSION 247 
As inhibitors of MCL-1 proceed to clinical testing, an important consideration is how these 248 
compounds might impact on the immune system. MCL-1 supports the survival of many 249 
different immune cell types but may also fulfil roles in mitochondrial dynamics and function 250 
in cells that can withstand partial MCL-1 inhibition. Treg cells are especially important in this 251 
context, given their heightened homeostatic turnover and critical role in maintaining immune 252 
tolerance. Here we report that only the anti-apoptotic function and not the metabolic function 253 
of MCL-1 is required for Treg cell homeostasis and suppression of autoimmunity. Deletion of 254 
MCL-1 deficiency in Treg cells resulted in a lethal autoinflammatory phenotype in mice that 255 
was wholly rescued by the concomitant deletion of the apoptotic ‘effector’ proteins BAK and 256 
BAX to at least 228 days of age. Furthermore, in contrast to other cell types, genetic deletion 257 
or pharmacological inhibition of MCL-1 did not alter cellular metabolism in Treg cells.  258 
 259 
These data are in accord with previous studies showing a key role for MCL-1 in preventing 260 
BAX/BAK-mediated apoptosis in cardiomyocytes and activated T cells 30, 42. However, 261 
although the IMM isoform of MCL-1 was reported to also have a role in cardiomyocyte 262 
metabolism 30 and in maintaining the integrity of the mitochondrial matrix in stem cells 31, our 263 
results suggest it is dispensable for these roles in Treg cells. These results would appear to be 264 
somewhat counterintuitive, as Treg cells have a greater reliance on oxidative phosphorylation 265 
for their ATP production and function than Tconv cells 43, 44. However, another BCL-2 family 266 
member BCL-XL, has also been reported to have a similar role in mitochondrial inner matrix 267 
stabilisation and a bioenergetic role in oxidative phosphorylation 45. It is possible that there is 268 
a cooperating or overlapping role of these proteins in cell metabolism that allows Treg cells to 269 
overcome the loss or inhibition of MCL-1. Alternatively, it may be the case that, as with cell 270 
type specific preferences for one pro-survival BCL-2 family member over others in inhibiting 271 
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apoptosis, either BCL-XL or MCL-1 may have precedence over the other in maintaining the 272 
metabolic function in different cell types. Yet another possibility is that neither MCL-1 nor 273 
BCL-XL are required to serve a role in the metabolic fitness of Treg cells. These considerations 274 
highlight the need to better understand the molecular mechanisms by which BCL-2 family 275 
members impact on mitochondrial dynamics and function. 276 
 277 
It is important to consider that all the experiments reported here were carried out under steady 278 
state conditions. In manipulating Treg cell populations for therapeutic utility, there may be 279 
different requirements for the inner mitochondrial matrix isoform of MCL-1 in conditions 280 
where the external environment may impact Treg cell metabolism and function, such as 281 
infection states or the tumour microenvironment 46, 47. For example, Hypoxia Inducible Factor 282 
1 alpha (HIF-1a) and mammalian target of rapamycin complex 1 (mTORC1) are up-regulated 283 
in Treg cells in the tumor microenvironment or infection settings, respectively. Both of these 284 
can induce different metabolic states in Treg cells 33, 48, 49, 50 that may change their requirement 285 
for IMM MCL-1.  286 
 287 
Nevertheless, our data from genetic and pharmacological models indicates that MCL-1 is not 288 
required for mitochondrial metabolism in Treg cells (and probably all lymphocytes) but 289 
functions only to antagonise the intrinsic pathway of apoptosis. These findings highlight 290 
context-specific requirements for MCL-1 among cell types and have bearing on the clinical use 291 
of inhibitors of MCL-1 for cancer treatment or manipulation of Treg cells in other diseases. 292 
 293 
METHODS AND MATERIALS 294 
Mice. Mcl1ΔFoxP3, BaxΔFoxP3Bak-/-, Mcl1ΔFoxP3Bak-/- and Mcl1ΔFoxP3BaxΔFoxP3Bak-/- mice were 295 
generated on, or backcrossed greater than 10 times onto, the C57BL/6 background. All mice 296 
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were housed at The Walter and Eliza Hall Institute of Medical Research (WEHI) under specific 297 
pathogen-free conditions, and experiments were carried out in accordance with the Animal 298 
Ethics Committee guidelines of the Melbourne Research Directorate. For experimentation, 299 
both female and male mice were used and mice of each genotype were randomized into groups. 300 
Disease development was monitored by frequent observation and post-mortem analysis. 301 
Cohorts of mice for the survival test were removed from the study at death, when mice lost 302 
more than 10% of peak body weight or when veterinary advice indicated likely death within 303 
48 h. The animal technicians assessing the welfare of the mice were blinded to the expected 304 
outcomes. 305 
Flow cytometry. Single-cell suspensions of organs were stained with fluorochrome- or biotin-306 
conjugated antibodies (produced by BioLegend except where indicated) to the following 307 
proteins: CD4 (clone GK1.5), CD8 (clone 53-6.7), CD25 (clone PC61.5), TCRβ (clone H57-308 
597), CD44 (clone IM7), CD62L (clone MEL-14), FOXP3 (eBiosciences, clone FJK-16) and 309 
MCL-1 (Produced in house at WEHI, clone 19c4-15). Intracellular staining for FOXP3 and 310 
MCL-1 was performed after fixation and permeabilization using the eBiosciences FOXP3 311 
staining kit. Sample data were acquired on an LSRII or Fortessa flow cytometer (BD 312 
Biosciences) and analyzed using FlowJo software (TreeStar). Mitochondrial membrane 313 
potential was assessed by labelling with 100 nM Mitotracker Orange CMTMRos for 20 min at 314 
37°C prior to addition of surface stains. 315 
IgE ELISA. Serum IgE concentrations were determined by ELISA using sheep anti-mouse Ig 316 
antibodies (Silenus Laboratories) as a capture reagent, and developed with mouse IgE-specific 317 
goat antibodies that had been conjugated with horseradish peroxidase (Southern 318 
Biotechnology).  319 
 320 
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Histology. Tissues were fixed in formalin, embedded, sectioned, and stained with 321 
haematoxylin and eosin (H&E). Leukocyte infiltration was scored as 0, 1, 2, 3, 4 and 5 322 
indicating none, trace, mild, moderate, severe or extremely severe lymphocytic infiltration and 323 
tissue destruction, respectively 51. The organs analyzed included the eyes, salivary glands, 324 
testes or ovaries, stomach, intestines, pancreas, kidney, liver, and lungs. Slides were imaged 325 
under the Nikon 90i Upright/Widefield research microscope and scored by a reviewer blinded 326 
to the mouse identity and genotype. 327 
Hematopoietic reconstitution. For generation of hematopoietic chimeras, adult 328 
C57BL/6.CD45.1 mice were irradiated with two doses of 5.5 Gy 3 h apart and reconstituted by 329 
intravenous injection of 2x106 bone marrow cells. Mice received 100 µg of THY1 mAb (clone 330 
T24) by the intra-peritoneal (i.p.) route 24 h following injection of BM cells to eliminate 331 
residual donor T cells and mice were then left for 8 weeks prior to analysis.  332 
Bioenergetic analysis. All bioenergetics and mitochondrial function analyses were performed 333 
using the Seahorse XF96 Extracellular Flux Analyser (Seahorse Bioscience). Sorted Treg cells 334 
were seeded into a CellTek (Corning) coated 96-well Seahorse plate in Seahorse XF assay 335 
media (pH 7.4; Agilent) supplemented with 5mM D-Glucose (Ajax Finechem), 1mM Sodium 336 
Pyruvate (Gibco) and 2mM L-Glutamine (Gibco) at a density of 6 x 105 cells/well. The OCR 337 
was measured sequentially after the addition of S63845 (Active Biochem), 1 μM oligomycin 338 
(Agilent), 1 μM FCCP (Agilent) and 0.5 μM rotenone and antimycin A (Agilent). 339 
In vitro apoptosis assays. Mouse spleen cells were cultured at 37°C in 10% CO2 for 48 h in 340 
RPMI-1640 media supplemented with 10% Fetal Calf Serum (Sigma) in the presence of 341 
varying concentrations of S63845 (Active Biochem) or dimethyl sulfoxide (DMSO; Sigma) 342 
vehicle control. Viability was assayed using the LIVE/DEAD fixable green dead cell stain kit 343 
(Invitrogen). Treg cells were identified with fluorochrome-conjugated antibodies (produced by 344 
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BioLegend except where indicated) to the following proteins: CD4 (clone GK1.5), CD25 345 
(clone PC61.5), CD3 (clone 17A2), and FOXP3 (eBiosciences, clone FJK-16). Intra-cellular 346 
staining for FOXP3 was performed after fixation and permeabilization using the eBiosciences 347 
FOXP3 staining kit. Sample data were acquired on a Fortessa flow cytometer (BD Biosciences) 348 
and analyzed using FlowJo software (TreeStar). 349 
In vitro Treg cell suppression assays. Splenic CD4+CD25+ Treg cells were FACS purified 350 
from WT control or Casp8ΔFoxp3 mice. CD4+CD25- Tconv cells from WT control mice were 351 
FACS purified as responder cells and labelled with 5 µM Cell Trace Violet (Life Technology). 352 
Antigen presenting cells (APCs) were splenocytes from WT mice irradiated with 30 Gy. 353 
Responder cells (1×104), APCs (4×104), and different concentrations of Tregs (1:1-1:10 354 
Treg:Tconv ratio, 1×104 – 1000 Tregs) were activated with 0.5 µg/mL anti-CD3 antibody in a 355 
96-well round bottomed plate. Cells were acquired by BD Fortessa, and the division index of 356 
responder cells was analyzed using FlowJo based on the dilution of Cell Trace Violet. 357 
 358 
Western Blotting. Splenic CD4+CD25+YFP+ Treg and CD4+CD25- YFP- Tconv cells were 359 
sorted, washed in PBS and resuspended in reducing SDS-PAGE sample buffer. Samples were 360 
electrophoresed on a 12% Tris-glycine gel (BioRad) and transferred to a PVDF membrane 361 
(BioRad). Membranes were blocked in 5% (w/v) low fat milk in TBS-Tween and probed with 362 
anti-MCL-1 antibody (Cat #600-401-394, Rockland, Gilberstcille, PA) followed by anti-rabbit 363 
IgG secondary antibody conjugated to horseradish peroxidase (Southern Biotech, Birmingham, 364 
AL). Blots were developed with Immobilon chemiluminescent substrate (Merck Millipore) and 365 
images were captured using a BioRad Chemidoc gel imaging system. 366 
 367 
Statistics. GraphPad Prism 7.0 software was used for statistical analysis. Statistical 368 
comparisons between two groups were made using the Welsh t-test. Statistical comparisons 369 
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between multiple groups were made using one-way ANOVA with a Tukey’s post hoc test for 370 
multiple comparisons. Survival comparisons of mouse genotypes were calculated using the 371 
log-ranked (Mantel-Cox) analysis. Differences were considered significant where the p value 372 
fell below 0.05 and were classified as follows: *P<0.05, **P<0.01, ***P<0.005, ****P<0.001, 373 
P>0.05 ns (not significant). 374 
 375 
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FIGURE LEGENDS 394 
Figure 1: Abrogation of BAK and BAX rescues the lethal autoinflammatory phenotype 395 
of Mcl1ΔFoxP3 mice 396 
(A) Representative flow cytometry histograms and (B) quantification of mean fluorescence 397 
intensity of MCL-1 expression in splenic CD4+ T cells from Mcl1ΔFoxP3Bak-/- mice detected by 398 
intracellular flow cytometry in CD4 T conv (CD4+ FOXP3-) and Treg cells (CD4+ FOXP3+). 399 
(C) Survival curve from birth to 125 days for wild-type, Mcl1ΔFoxP3, BaxΔFoxP3Bak-/-, 400 
Mcl1ΔFoxP3BaxΔFoxP3Bak-/- and Mcl1ΔFoxP3Bak-/- mice. P-value <0.001 calculated by Log-ranked 401 
(Mantel-Cox) test. (D) Plasma IgE concentrations in 42-125 day old Mcl1ΔFoxP3 mice (taken at 402 
time of death or euthanasia) and 125 day old wild-type, Bak-/-BaxΔFoxP3 and Mcl1ΔFoxP3Bak-/-403 
BaxΔFoxP3 counterparts. (E) Representation of hematoxylin and eosin stained sections of lung, 404 
pancreas and salivary gland from 42-125 day old Mcl1ΔFoxP3 mice (taken at time of death or 405 
euthanasia) and 125 day old wild-type, Bak-/-BaxΔFoxP3 and Mcl1ΔFoxP3Bak-/-BaxΔFoxP3 406 
counterparts (Scale bar:100 µm). Arrows indicate areas of lymphocytic infiltration. (F) Graph 407 
of lymphocytic infiltration score in the lung, salivary gland, and pancreas in mice of the 408 
indicated genotypes. A higher lymphocytic infiltration score denotes more severe infiltration 409 
and organ destruction. Data in (A) and (B) is representative of 2 independent experiments of 410 
3-4 mice per experiment. Data in (B) is mean ± s.d. ****P=0.0003 based on Welch’s t test. 411 
Data in (D) and (F) are mean ± s.d. for 7-10 mice per genotype. *P<0.05, **P<0.01, 412 
***P<0.005, ****P<0.001 based on Tukey’s multiple comparison test. 413 
 414 
Figure 2: Concomitant loss of BAK and BAX prevents the depletion of Treg cells caused 415 
by the deletion of MCL-1 416 
(A) Representative flow cytometry plots, and (B) percentages from total CD4 cells (left) and 417 
absolute numbers (right) of CD4+FOXP3+ cells in the thymus of 42-125 day old Mcl1ΔFoxP3 418 
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mice (taken at time of death or euthanasia) and 125 day old wild-type, Bak-/-BaxΔFoxP3 and 419 
Mcl1ΔFoxP3Bak-/-BaxΔFoxP3 counterparts. (C) Representative flow cytometry plots, and (D) 420 
percentages from total CD4 cells (left) and absolute numbers (right) of CD4+CD25+FOXP3+ 421 
cells in the spleen and lymph nodes of 42-125 day old Mcl1ΔFoxP3 mice (taken at time of severe 422 
illness or sacrifice for healthy controls) and 125 day old wild-type, Bak-/-BaxΔFoxP3 and 423 
Mcl1ΔFoxP3Bak-/-BaxΔFoxP3 counterparts. Data in (A) and (C) are representative of four 424 
independent experiments with 1-5 mice in each group. Numbers indicate percentages of cells 425 
within the gate. Data in (B) and (D) represent mean ± s.d. for 8-20 mice per genotype. *P<0.05, 426 
**P<0.01, ***P<0.005, ****P<0.001 based on Tukey’s multiple comparison test. 427 
 428 
Figure 3: The lethal lymphocytic infiltrative disease observed in Mcl1DFoxP3 mice is a 429 
consequence of a constitutively activated immune state. 430 
(A) Representative flow cytometry plots of CD44 and CD62L expression on CD4+FOXP3- and 431 
CD8+ cells from the spleens of 42-125 day old Mcl1ΔFoxP3 mice (taken at time of severe illness 432 
or sacrifice in the case of healthy controls) and 125 day old wild-type, BaxΔFoxP3Bak-/- and 433 
Mcl1ΔFoxP3BaxΔFoxP3Bak-/- counterparts. Numbers indicate percentages of cells in each 434 
quadrant. Data in (A) are representative of four independent experiments with 1-5 mice in each 435 
group. (B) Percentages from total CD4 or CD8 cells (left) and absolute numbers (right) of 436 
activated CD62LlowCD44hi CD4 and CD8 cells in mice of the indicated genotype. Data 437 
represent mean ± s.d. for 8-20 mice per genotype. *P<0.05, **P<0.01, ***P<0.005, 438 
****P<0.001 based on Tukey’s multiple comparison test.  439 
 440 
Figure 4: MCL-1 deficient Treg cells do not have altered metabolic capacity.  441 
(A) Representative mitochondrial membrane potential in wild-type, Mcl1ΔFoxP3, BaxΔFoxP3Bak-442 
/- and Mcl1ΔFoxP3Bax ΔFoxP3Bak-/- Treg cells (TCRb+ CD4+ FOXP3+ lymphocytes), measured as 443 
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accumulation of MitoTracker Orange dye. Representative traces (B), and calculated basal (C) 444 
and maximal (D) Oxygen Consumption Rate (OCR) measurements performed on sorted 445 
YFP+CD4+CD25+ cells from wild type, BaxΔFoxP3Bak-/- and Mcl1ΔFoxP3BaxΔFoxP3Bak-/- mice at 446 
basal levels and after subsequent additions of the ATP synthase inhibitor oligomycin, 447 
uncoupler FCCP, RC complex I inhibitor rotenone and RC complex III inhibitor antimycin A 448 
(AA). Representative traces (E), and calculated basal (F) and maximal (G) OCR and 449 
measurements performed on sorted YFP+CD4+CD25+ cells from Bak-/- chimeric mice treated 450 
with DMSO (vehicle), 0.1 µM or 1 µM MCL-1 inhibitor S63845 at basal levels, and after 451 
subsequent additions of the oligomycin, FCCP, rotenone and antimycin A. Data in (A) are 452 
representative of three independent experiments with n=2-5 mice per group. Data in (B-D) are 453 
mean ± s.d. are representative of three independent experiments. In each experiment, technical 454 
replicate wells of 600,000 cells pooled from n=2-5 mice were assessed. Data in (E) are a 455 
representative graph from one experiment of two independent experiments. Data in (F) and 456 
(G) are mean ± s.d. of data pooled from two independent experiments. 457 
 458 
Supplementary Figure 1: BaxΔFoxP3Bak-/- Treg cells express the OMM and IMM MCL-1 459 
isoforms and have comparable suppressive ability to wild type cells. 460 
(A) Quantification of undivided Tconv cells from an in vitro Treg cell suppression assay at 461 
various ratios of CD4+CD25+YFP+ cells:CD4+CD25- Tconv cells from WT control or 462 
BaxΔFoxP3Bak-/- mice. Data is the average of triplicate measurements and representative of 3 463 
independent experiments. (B)  Western blot detection of OMM (~40kDa) and IMM (~31kDa) 464 
MCL-1 isoforms in CD4+ conventional and regulatory T cells  BaxΔFoxP3Bak-/-. 465 
 466 
Supplementary Figure 2: MCL-1 deficient Treg cells do not have altered metabolic 467 
capacity. 468 
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Calculated basal (A, C) and maximal (B, D) Oxygen Consumption Rate (OCR) measurements 469 
performed on sorted YFP+CD4+CD25+ cells from BaxΔFoxP3Bak-/- and Mcl1ΔFoxP3BaxΔFoxP3Bak-470 
/- mice at basal levels and after subsequent additions of oligomycin, FCCP, rotenone and 471 
antimycin A (AA). Data represent mean ± s.d. for replicate wells within one experiment and in 472 
combination with data from three independent experiments.  473 
 474 
Supplementary Figure 3: S63845-induced killing of Treg cells is rescued by Bak and Bax 475 
deletion. 476 
Cell viability, normalised to vehicle treated control cells, of CD4+FOXP3+ Treg cells isolated 477 
from wild-type, Bak-/- and BaxΔFoxP3Bak-/- mice, treated in vitro for 48 h with 0.1 µM, 1 µM or 478 
10µM of S63845. Data in are mean ± s.d. for two independent experiments.  479 
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